Evidence map›Paper›PMID 39907459›Full record

ArticleMicrobiology spectrum2025

Characterization of sulopenem antimicrobial activity using

Joshua M Maher, Michael D Huband, Jill M Lindley, Paul R Rhomberg, Steven I Aronin, Sailaja Puttagunta, Mariana Castanheira

Abstract read
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. A systematic review of data on the resistance of uropathogens to sulopenem.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Pooled it
  2. Article
  3. In vitro activity of the novel β-lactamase inhibitor FL058 combined with meropenem against KPC- or NDM-producing enterobacterales and Pseudomonas aeruginosa.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Joshua M MaherElement Iowa City-JMI Laboratories, North Liberty, Iowa, USA.ORCID 0000-0002-2841-6855
Michael D HubandElement Iowa City-JMI Laboratories, North Liberty, Iowa, USA.ORCID 0000-0002-9769-9019
Jill M LindleyElement Iowa City-JMI Laboratories, North Liberty, Iowa, USA.
Paul R RhombergElement Iowa City-JMI Laboratories, North Liberty, Iowa, USA.
Steven I AroninIterum Therapeutics, Old Saybrook, Connecticut, USA.ORCID 0000-0002-4041-043X
Sailaja PuttaguntaIterum Therapeutics, Old Saybrook, Connecticut, USA.
Mariana CastanheiraElement Iowa City-JMI Laboratories, North Liberty, Iowa, USA.ORCID 0000-0003-0126-1782

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sulopenem is an oral and intravenous penem antibiotic in clinical development for treatment of urinary tract and intra-abdominal infections caused by multidrug-resistant pathogens. This study evaluated

Indexed as

Anti-Bacterial AgentsEscherichia coliKlebsiella pneumoniaeDrug Resistance, Multiple, BacterialDrug SynergismEscherichia coli InfectionsHumansKlebsiella InfectionsMicrobial Sensitivity TestsMicrobial ViabilityUrinary Tract InfectionsAnti-Bacterial Agentsantimicrobial agentspost-antibiotic effectsusceptibility testingsynergismtime-kill curvesurinary tract infection

Identifiers

PMID39907459
PMCPMC11878024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.